Related Experiment Video

Updated: Oct 2, 2025

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

11.1K

Effective drug combinations in breast, colon and pancreatic cancer cells

Patricia Jaaks1, Elizabeth A Coker1, Daniel J Vis2,3

  • 1Wellcome Sanger Institute, Cambridge, UK.

Nature
|February 24, 2022
PubMed

Insights

Identifying effective anti-cancer drug combinations is crucial for new treatments. This study found that drug synergy is rare and context-dependent, but identified specific combinations effective in certain cancer types.

Area of Science:

  • Oncology
  • Pharmacology
  • Genomics

Background:

  • Drug resistance and limited treatment options necessitate novel anti-cancer strategies.
  • The vast number of potential drug combinations makes clinical testing infeasible.
  • Systematic identification of effective drug combinations and their contexts is needed.

Purpose of the Study:

  • To evaluate the efficacy of 2,025 clinically relevant two-drug combinations across diverse cancer cell lines.
  • To identify biomarkers for synergistic drug combinations and their specific molecular contexts.
  • To accelerate the development of rational combination cancer therapies.

Main Methods:

  • Screening of 2,025 two-drug combinations in 125 molecularly characterized breast, colorectal, and pancreatic cancer cell lines.
  • Integration of multi-omic molecular features to identify predictive biomarkers.
  • In vivo validation of synergistic drug combinations in tumor xenografts.

Main Results:

  • Drug synergy was found to be rare and highly context-dependent.
  • Combinations of targeted agents showed the highest likelihood of synergy.
  • Specific synergistic combinations were identified for basal-like breast cancer and microsatellite-stable or KRAS-mutant colon cancer.
  • Irinotecan and CHEK1 inhibition demonstrated synergy in specific colon cancer subtypes, leading to apoptosis and tumor growth suppression.

Conclusions:

  • Synergistic anti-cancer drug combinations are context-specific and rare.
  • Multi-omic data can identify biomarkers for predicting synergistic drug responses.
  • This study provides a valuable resource for guiding the rational development of combination cancer therapies in distinct molecular subpopulations.

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.4K
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.3K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
5.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K